Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021. Management will engage in a virtual fireside chat at 8:00 a.m. ET and will be available for one-on-one meetings throughout the day. Investors can access a live audio webcast of the chat on the company's website, which will be archived for 30 days. Aclaris focuses on developing innovative drug candidates for immuno-inflammatory diseases, leveraging a strong R&D pipeline.
Details
News Market Reaction – ACRS
The recorded move for ACRS in the trading session of this news was +6.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00 a.m. ET. Management will be available February 25th throughout the day for virtual one-on-one meetings.
A live audio webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Contact
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.